 Home > Active Ingredient News > Drugs Articles > Biotech stocks are on a roller coaster, but they continue to outperform!

Biotech stocks are on a roller coaster, but they continue to outperform!

 Last Update: 2023-01-05
 Source: Internet
 Author: User

Tags

vw supply

drugs com interactions

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since 2020, Pfizer and its partners BioNTech, along with Moderna and Johnson & Johnson, have launched three Covid-19 vaccines, which have become the focus
of the biomedical industry.
But as Covid-19 has become more and more coexisting with humanity for a long time, other concerns surrounding the economy and inflation have become the focus
of society.
Investor's Business Daily said shares of biotech industry groups fell
sharply for 16 consecutive months.

After hitting rock bottom in mid-June, biotech stocks appear to have gained a foothold this fall
.
Nowadays, stock prices are mostly in a sideways trend
.
However, this happens
in a fierce market competition.
Biotechnology Industry Group at Investor's Business Daily ranked 16th out of 197 industry groups
.
Meanwhile, the pharmaceutical group ranks
153rd.

In terms of fundamentals and technical indicators, as well as 12 months of performance, the top five of today's best biotech stocks are: 1.
Catalyst Pharmaceuticals； 2、Genmab； 3、Harmony Biosciences； 4、Vertex Pharmaceuticals； 5、Dynavax Technologies
。

No.
1 biotech stock: Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is the number one biotech stock, an industry group of more than 800 companies that is the industry leader
.

Its only product is Firdapse, a drug
for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
LEMS is a rare autoimmune disease that weakens muscle strength and often occurs in
lung cancer patients.
Although sales of the drug are growing, Catalyst Pharmaceuticals is looking to acquire a second or third offering
through an outright acquisition or licensing transaction.
Catalyst stock is also on the
list of technology leaders.
Stocks in IBD Ranked second
in the list of 50 elite growth stocks.

Figure 1 Product pipeline (Source: Catalyst official website)

According to IBD Digital's data, bullishly, is that CPRX stocks have the best composite rating of 99
.
In terms of fundamentals and technical indicators, this puts biotech stocks in the top 1%
of all stocks.
Its 12-month performance, as measured by its relative strength rating, also ranked in the top 1%
of all stocks.

Genmab's killer app: cancer treatment drugs

Genmab sells cancer treatment drugs
.
The company works with large biopharmaceutical companies, including AbbVie, Johnson & Johnson, and Horizo Therapeutics and Seagen
.
Genmab announced in July that AbbVie would submit a marketing
authorization application for Epcoritamab (DuoBody-CD3xCD20®) to the European Medicines Agency for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

In August, Genmab announced an expanded global strategic collaboration with BioNTech to expand the commercialization
of novel immunotherapies for the treatment of cancer patients.
The scope of the collaboration expanded to include the development of single-specific antibody candidates to address malignant solid tumors; Leveraging Genmab's proprietary HexaBody® technology platform to develop novel single-specific antibodies, Genmab and BioNTech will continue to split costs and profits
on a 50:50 ratio.

Figure 2 Part of the product pipeline (Source: Genmab official website)

In the third quarter of September, earnings and sales grew strongly to 53 cents per share and $551 million
, respectively.
Both indicators also easily exceeded expectations
.
Now, Genmab is expanding its drug pipeline into new solid tumors and blood
cancers.
The stock has a maximum composite rating of 99 and a relative strength rating of 95
.
In addition, its RS line also hit a new high
.
In addition, Genmab is a technology leader at IBD Ranked 14th out of the 50 index
.

Opportunities in Harmony Biosciences products

Harmony Biosciences has made a name for itself with one product: pitolisant
.
The company sees the drug as an "opportunity in the product.
"

Today, pitolisant is approved for the treatment of narcolepsy, a drug known as Wakix
.
But Harmony is also studying pitolisant in other conditions, including a sleep disorder called idiopathic narcolepsy, a genetic disorder called Prader-Willi syndrome and a muscle weakness disorder ankylosing dystrophy
.
Idiopathic narcolepsy IH (Idiopathic Hypersomnia, IH) is a rare chronic neurological disorder characterized by excessive sleepiness
during the day despite adequate or even prolonged sleep.
People with IH experience severe excessive sleepiness as well as symptoms of sleep inertia (difficulty waking out of sleep for long periods of time) and "brain fog" (impaired cognition, attention, and alertness
).
According to research data, the number of patients diagnosed with IH in the United States is between
30,000 and 40,000.
Harmony is also testing early products
for Prader-Willi syndrome.
Prader-Willi causes many behavioral and intellectual problems
.
It can also lead to short
stature.

Figure 3 Harmony Biosciences Wakix (Source: Harmony official website)

Harmony's third-quarter product net revenue was $117.
2 million, compared to $80.
7 million in the same period in 2021, an increase of 45.
2% compared to the same period in 2021, with continued organic demand driving strong commercial sales
at WAKIX.
As of September 30, 2022, the average number of patients using WAKIX increased to approximately 4,600.

The biotech stock is also a technology leader, ranking ninth
in the IBD 50 index.
The stock has a perfect composite rating of 99 and a strong RS rating
of 97.

Vertex Pharmaceuticals - cystic fibrosis giant

In terms of market capitalization, Vertex Pharmaceuticals is one of the
most valuable biotech stocks.
It ranks fourth
after Amgen, Gilead Sciences and Regeneron Pharmaceuticals.
The company is a market leader
in cystic fibrosis drugs.

Vertex The Pharmaceuticals portfolio approach focuses on bringing multiple compounds into clinical research and using clinical data to inform
drug discovery and development.
The work began in the lab to design, synthesize and test tens of thousands of compounds
.
Only the most promising potential drugs will enter clinical trials
.
To date, there are 10 candidates for investigational cystic fibrosis (Cystic Fibrosis, CF) drugs have entered this phase
in several countries.

Vertex advanced the first of these potential drug discoveries to clinical development
in 2006.
Since then, four innovative drugs have become available to certain eligible CF patients, and research is ongoing to continue to discover and develop drugs
for potential CF patients.

Figure 4 Part of the product pipeline (Source: Vertex Pharmaceuticals official website)

Third-quarter sales — dominated by its triple therapy, Trikafta, jumped 18 percent to $2.
33 billion
.
But it's now expanding into other areas
.
Vertex and Crispr Therapeutics (CRSP) collaborated to target gene editing
for two blood disorders.
In addition, Vertex recently announced its plans
to acquire its diabetes treatment partner's privately held ViaCyte for $320 million.
The companies are testing a cell-replacement drug
to treat type 1 diabetes.

In addition, Vertex is testing treatments
for liver and kidney disease, Duchenne muscular dystrophy and pain.

According to MarketSmith.
com, the biotech stock has a perfect composite rating and a relative strength rating
of 95.
Vertex is still Tech Leader
.

Dynavax is using vaccine technology to make great strides

Dynavax Technologies is one of the smaller biotech stocks on the list, but its share price is trending
up rapidly.
The company sells a hepatitis B vaccine called Heplisav-B and has acquired a partnership with Indian company Biological Emergency authorization
for Covid-19 vaccines in collaboration with E.
Limited.
Dynavax is also developing its vaccine adjuvant
in whooping cough, shingles and plague.
Adjuvants enhance the typical immune response
to vaccines.

In the third quarter, Dynavax reported sales of $167.
7 million
.
According to FactSet, sales surged 55 percent, beating expectations to $159.
4 million
.
Adjusted earnings per share were 43 cents, reversing losses in the year-ago quarter and beating expectations by 13 cents
.

Since hitting a recent bottom in late September, the biotech stock has been climbing
steadily.
The stock has a relative strength rating of 84 and a bullish composite rating of 97
.
Dynavax stock has also recently soared above
its key moving average.

Net revenue from HEPLISAV-B® vaccine products was $37.
5 million in the third quarter, up 65%
from $22.
7 million in the third quarter of 2021.
The market share of the target customer DeNahuax field sales team increased to approximately 43%, and the total market share increased from approximately 32% and 25% in the third quarter of 2021 to approximately 32%
in the third quarter of 2022, respectively.
CpG1018 adjuvant revenue for the third quarter of 2022 was $126.
3 million, up 50%
from 84.
3 million in the third quarter of 2021.

Figure 5 Product pipeline (Source: Dynavax official website)

Dynavax has established a global portfolio of commercial supply protocols for CpG1018 adjuvants and currently supports the development of COVID-19 vaccines
across various vaccine platforms.
The Company reaffirms its commitment to CpG for the full year 2022 1018 Adjuvant COVID-19 Supply Revenue is expected to be between $550 million and $600 million, and based on committed orders placed by our CSA, gross margin is expected to be approximately 60%
for the full year.

Resources:

[1]

[1] [2]https://xueqiu.
com/9271268436/235735330

[2]https://xueqiu.
com/9271268436/235735330

[3]

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.